1-10 of 10
Muhammad Jalaluddin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7261–7263.
https://doi.org/10.1182/blood-2022-163809
Published: 2022
Journal Articles

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Kimberley Dilley, MD MPH, Jason Harb, PhD, Muhammad Jalaluddin, PhD, Jessica E. Hutti, PhD, Jalaja Potluri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-139247
Published: 2020
Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-134710
Published: 2020
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

Jeffrey Lee Wolf, David Siegel, Jeffrey Matous, Sagar Lonial, Hartmut Goldschmidt, Stefan Schmitt, Ravi Vij, Margarida De Malgalhaes-Silverman, Rafat Abonour, Muhammad Jalaluddin, Martha Li, Katharine Hazell, Priscille M. Bourquelot, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Spencer, Jean-Luc Harousseau, Joan Bladé
Journal: Blood
Blood (2008) 112 (11): 2774.
https://doi.org/10.1182/blood.V112.11.2774.2774
Published: 2008
Journal Articles

A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma

Davi d Siegel, Orhan Sezer, Jesus F. San Miguel, Maria-Victoria Mateos, Ian Prosser, Michele Cavo, Muhammad Jalaluddin, Katharine Hazell, Priscille M. Bourquelot, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 2781.
https://doi.org/10.1182/blood.V112.11.2781.2781
Published: 2008
Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

Andrey Zaritskey, Giuliana Alimena, Lech Konopka, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Anna Turkina, Gert J. Ossenkoppele, Stuart L. Goldberg, Bayard Powell
Journal: Blood
Blood (2008) 112 (11): 4254.
https://doi.org/10.1182/blood.V112.11.4254.4254
Published: 2008
Journal Articles

A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

François Guilhot, Viviane Dubruille, Aleksander B. Skotnicki, Andrey Hellmann, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Elisabetta Abruzzese, Luke Akard
Journal: Blood
Blood (2008) 112 (11): 4263.
https://doi.org/10.1182/blood.V112.11.4263.4263
Published: 2008
Journal Articles

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, MD, Andrew Spencer, H. Miles Prince, Kapil N. Bhalla, Thomas Fischer, Angela Liu, Kathryn Parker, Muhammad Jalaluddin, Glen Laird, Margaret Woo, Jeffrey W. Scott, Daniel J. DeAngelo
Journal: Blood
Blood (2008) 112 (11): 958.
https://doi.org/10.1182/blood.V112.11.958.958
Published: 2008